Visiopharm is pleased to announce that Johanne Louise Brændgaard has been appointed Chief Marketing Officer.
Johanne will play a vital part in executing Visiopharm’s strategy in AI-driven precision and high-throughput pathology, with responsibility for brand strategy and awareness, customer experience and commercial marketing.
Johanne brings extensive global experience of sales, marketing, and product management within the medical technology industry from previous positions at Cook Medical and Getinge. She also has experience from the telecommunications and venture capital industries.
Johanne is currently on the board of ADDvise AB, having previously been on the board of Acarix AB.
Johanne has a master’s degree in International Business Economics from Aalborg University in Denmark.
Michael Grunkin, Visiopharm CEO said:
“We are delighted to welcome Johanne. She is a great fit with the team, culture and values of the company and brings a personality with her that will naturally facilitate cross-functional collaboration. That, in combination with her extensive experience in the medical technology industry, will be a great asset as we continue to move forward with our ambitious marketing goals.”
Johanne Louise Brændgaard said:
“I’m excited to have joined Visiopharm at this critical time and be part of the mission to transform pathology through our AI-driven solutions. This will enable our customers to have a much stronger foundation for making diagnostic and treatment decisions for cancer patients, which in turn can have significant socio-economic impact due to lower rates of misdiagnosis and ineffective treatment.”Visiopharm Categories: Press Releases 16842 How image analysis and artificial intelligence support digital pathology-enabled precision medicine today and what to expect in the future
Digital Transformation in Pathology podcast in collaboration with Dr Aleksandra Zuraw from Digital Pathology Place.
In the second of this special two-part podcast celebrating our twentieth anniversary, hear from Visiopharm founder and CEO Michael Grunkin.
Other ways to listen
Apple Podcasts | Spotify
With the regulatory approvals of whole slide imaging systems, digital pathology became the modality for routine diagnostics. Digitalization of pathology is aiming at increasing precision and productivity in the pathology lab, but the adoption of this field is slower than expected.
One of the causes of the slow adoption is that going digital in a pathology lab means a much bigger investment than just the cost of the whole slide scanners for slide digitization. Additional costs include digital storage and infrastructure, slide and workflow management and connectivity to lab information systems.
Because the improvements in precision and productivity gained by going digital are modest at best, a higher value is expected from image analysis and artificial intelligence.
The research and diagnostic applications of image analysis have been explored for decades already and many have found great use in the research-diagnostics continuum. However, a large need for standardization of tissue diagnostic assays remains unmet.
Standardization of the staining and of the diagnostic interpretation of tests would tremendously benefit pathology and patient care. So far, the standardization efforts focused on the interpretation part of the puzzle. Several quantification algorithms have been developed, many of which received regulatory clearance. At the same time the IHC assays on which the algorithms are based often lack standardization, and this is where more effort should be put.
Currently only pathology institutions that go fully digital reap the digital pathology benefits. There is not an efficient way to start slowly, rather it seems to be “all or nothing”. Enabling institutions to embark on the digital pathology journey in an incremental fashion would change the digital pathology landscape and significantly increase the adoption of this technology.
The more value on different fronts digital pathology can provide to institutions and patients, the more the adoption will increase. And we have not yet explored all the ways in which value can be provided.
Listen to full episode to learn about it in more detail and visit Visiopharm’s website, to learn how they are contributing to the digital transformation in pathology.
Length: 20 minutes.
- To listen to part one of this podcast, click here.
- Let us know what you think of the episode and any topics you would like us to cover in the future by sending us an email at: email@example.com or contacting us on social media.
If you enjoyed this episode, you might also like our other digital pathology podcasts, such as:
- Why and how should digital pathology be implemented into clinical practice?
- Why and how should pathologists keep up with AI?
- Reimbursement for digital pathology in the clinic – how does that work?
Augsburg University Hospital, one of Germany’s leading hospitals, has selected Visiopharm, a world-leading developer of precision AI image analysis software, to realise its ambition of becoming a digital pathology powerhouse.
The partnership will see Visiopharm implement its digital pathology software to accelerate the hospital’s diagnostic workflows, to provide faster diagnoses to patients and even with a higher degree of accuracy.
The hospital will be using Visiopharm’s CE-IVD marked APPs, starting with HER2 and then expanding to other APPs like ER, PR, Ki67 and lymph node metastasis detection to quantify breast cancer biomarkers.
The partnership builds on an existing collaboration between Visiopharm and Prof Ralf Huss, a member of Visiopharm’s Scientific Advisory Board and Head of the Center for Digital Medicine at Augsburg Hospital. In a collaborative paper published recently, Augsburg pathologists reported on the use of Visiopharm’s AI software to discover an impaired maturation of dendritic cells leading to an inadequate T-cell response in severe cases of COVID patients at the hospital.
Augsburg and Visiopharm intend to collaborate on demonstrating the value of introducing digital pathology and AI into the clinical workflow with the aim for Augsburg to confirm its role as a reference site for other hospitals to base best practice on. This will involve conducting scientific and rigorous studies, as well as developing and testing new algorithms for diagnostic decision support, stain quality management and slide control.
To ensure a seamless workflow, Visiopharm software will be integrated into the existing pathology workflow of the pathology department, together with NEXUS AG, which is the provider of the laboratory information system used in Augsburg.
Michael Grunkin, Visiopharm CEO said:
“We’re excited to be given this opportunity to help Augsburg University Hospital achieve their digital transformation ambition. It’s an exciting milestone to modernize their pathology services and show the value of a fully digital workflow in improving patient care. Throughout the project, we very much look forward to sharing what we achieve together with the healthcare community.”
Prof Bruno Märkl, Institute for Pathology and Molecular Diagnosis, Augsburg University Hospital said:
“This is the beginning of a new chapter for our hospital’s future. With Visiopharm’s AI software we can introduce a truly digital workflow, which includes diagnostic decision support and enables standardization of stain quality. The whole team is determined to deliver the best quality of care for our patients, and we cannot do this without digitizing our pathology workflow. Hopefully we can inspire other hospitals to follow in our footsteps.”
Visiopharm® is a world-leading developer of precision AI image analysis software. Their pioneering image analysis tools support thousands of scientists, pathologists, and image analysis experts in academic institutions, biopharmaceutical industry, and diagnostic centers. AI-based image analysis and tissue mining tools support research and drug development research worldwide, while CE-IVD APPs support primary diagnostics. With the most advanced and sophisticated artificial intelligence and deep learning, Visiopharm delivers tissue data mining tools, precision results, and workflows.
Visiopharm was founded in 2002 and is privately owned. The company operates internationally with over 900 licenses and countless users in more than 40 countries. The company headquarters are in Denmark’s Medicon Valley, with offices in Sweden, England, Germany, Netherlands and United States.Visiopharm Categories: Press Releases